MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.76 EUR
0 (0%)
We assign a fundamental rating of 6 out of 10 to MED. MED was compared to 32 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
- MED had positive earnings in the past year.
- MED had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
- MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of MED (3.85%) is better than 65.63% of its industry peers.
- MED's Return On Equity of 14.15% is fine compared to the rest of the industry. MED outperforms 71.88% of its industry peers.
- MED has a better Return On Invested Capital (7.06%) than 68.75% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 7.02%.
- The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
- The Profit Margin of MED (4.40%) is better than 78.13% of its industry peers.
- MED's Profit Margin has improved in the last couple of years.
- With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 78.13% of the companies in the same industry.
- In the last couple of years the Operating Margin of MED has grown nicely.
- MED's Gross Margin of 84.08% is amongst the best of the industry. MED outperforms 84.38% of its industry peers.
- In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
- MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, MED has about the same amount of shares outstanding.
- The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
- MED has an Altman-Z score of 1.59. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
- MED has a Altman-Z score of 1.59. This is in the lower half of the industry: MED underperforms 65.63% of its industry peers.
- MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
- MED has a Debt to FCF ratio (9.63) which is in line with its industry peers.
- MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
- MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.59 |
ROIC/WACC1.46
WACC4.84%
2.3 Liquidity
- A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
- The Current ratio of MED (1.93) is better than 90.63% of its industry peers.
- A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
- With an excellent Quick ratio value of 1.89, MED belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
- MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
- MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
- MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
- Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
- The Earnings Per Share is expected to grow by 20.09% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 3.42% on average over the next years.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 5.08, which indicates a rather cheap valuation of MED.
- 100.00% of the companies in the same industry are more expensive than MED, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of MED to the average of the S&P500 Index (27.33), we can say MED is valued rather cheaply.
- The Price/Forward Earnings ratio is 5.52, which indicates a rather cheap valuation of MED.
- 100.00% of the companies in the same industry are more expensive than MED, based on the Price/Forward Earnings ratio.
- MED's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.52 |
4.2 Price Multiples
- 93.75% of the companies in the same industry are more expensive than MED, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.84 | ||
| EV/EBITDA | 2.9 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MED may justify a higher PE ratio.
- MED's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.24
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
- MED has a Yearly Dividend Yield of 1.13%. Purely for dividend investing, there may be better candidates out there.
- Compared to an average industry Dividend Yield of 1.57, MED has a dividend in line with its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.91, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (1/14/2026, 7:00:00 PM)
3.76
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2025-11-04
Earnings (Next)03-26 2026-03-26
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap178.60M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (56.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.52 | ||
| P/S | 0.22 | ||
| P/FCF | 3.84 | ||
| P/OCF | 1.85 | ||
| P/B | 0.72 | ||
| P/tB | 0.8 | ||
| EV/EBITDA | 2.9 |
EPS(TTM)0.74
EY19.68%
EPS(NY)0.68
Fwd EY18.13%
FCF(TTM)0.98
FCFY26.04%
OCF(TTM)2.04
OCFY54.13%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.24
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.59 |
F-Score8
WACC4.84%
ROIC/WACC1.46
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.08 and the Price/Book (PB) ratio is 0.72.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.